25 XP   0   0   10

Ilyang Pharm
Buy, Hold or Sell?

Let's analyse Ilyang together

PenkeI guess you are interested in Ilyang Pharm. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Ilyang Pharm. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Ilyang Pharm

I send you an email if I find something interesting about Ilyang Pharm.

Quick analysis of Ilyang (30 sec.)










What can you expect buying and holding a share of Ilyang? (30 sec.)

How much money do you get?

How much money do you get?
₩0.43
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
₩10,928.66
Expected worth in 1 year
₩-9,901.72
How sure are you?
80.0%

+ What do you gain per year?

Total Gains per Share
₩-20,209.44
Return On Investment
-141.0%

For what price can you sell your share?

Current Price per Share
₩14,330.00
Expected price per share
₩13,130 - ₩16,250
How sure are you?
50%

1. Valuation of Ilyang (5 min.)




Live pricePrice per Share (EOD)

₩14,330.00

Intrinsic Value Per Share

₩-9,348.85 - ₩15,594.81

Total Value Per Share

₩1,579.80 - ₩26,523.47

2. Growth of Ilyang (5 min.)




Is Ilyang growing?

Current yearPrevious yearGrowGrow %
How rich?$137.4m$204.2m-$66.8m-48.6%

How much money is Ilyang making?

Current yearPrevious yearGrowGrow %
Making money$8m$13.4m-$5.4m-67.0%
Net Profit Margin4.4%5.0%--

How much money comes from the company's main activities?

3. Financial Health of Ilyang (5 min.)




What can you expect buying and holding a share of Ilyang? (5 min.)

Welcome investor! Ilyang's management wants to use your money to grow the business. In return you get a share of Ilyang.

What can you expect buying and holding a share of Ilyang?

First you should know what it really means to hold a share of Ilyang. And how you can make/lose money.

Speculation

The Price per Share of Ilyang is ₩14,330. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Ilyang.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Ilyang, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₩10,928.66. Based on the TTM, the Book Value Change Per Share is ₩-5,207.59 per quarter. Based on the YOY, the Book Value Change Per Share is ₩1,208.74 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₩155.23 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Ilyang.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps0.450.0%0.450.0%0.740.0%0.510.0%0.260.0%
Usd Book Value Change Per Share-3.650.0%-3.650.0%0.850.0%-0.080.0%0.050.0%
Usd Dividend Per Share0.110.0%0.110.0%0.150.0%0.200.0%0.190.0%
Usd Total Gains Per Share-3.540.0%-3.540.0%1.000.0%0.120.0%0.240.0%
Usd Price Per Share10.96-10.96-13.55-21.20-23.22-
Price to Earnings Ratio24.42-24.42-18.19-45.87-52.78-
Price-to-Total Gains Ratio-3.10--3.10-13.56-18.20-126.88-
Price to Book Ratio1.43-1.43-1.20-2.25-2.69-
Price-to-Total Gains Ratio-3.10--3.10-13.56-18.20-126.88-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share10.031
Number of shares99
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.110.20
Usd Book Value Change Per Share-3.65-0.08
Usd Total Gains Per Share-3.540.12
Gains per Quarter (99 shares)-350.1311.70
Gains per Year (99 shares)-1,400.5146.78
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
143-1444-141180-3337
286-2887-2812160-6784
3129-4331-4213240-100131
4172-5774-5614320-133178
5215-7218-7015400-166225
6258-8661-8416480-200272
7301-10105-9817560-233319
8344-11548-11218640-266366
9387-12992-12619720-299413
10430-14435-14020800-333460

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%8.02.00.080.0%12.02.00.085.7%
Book Value Change Per Share0.01.00.00.0%2.01.00.066.7%4.01.00.080.0%6.04.00.060.0%9.05.00.064.3%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%14.00.00.0100.0%
Total Gains per Share0.01.00.00.0%2.01.00.066.7%4.01.00.080.0%8.02.00.080.0%11.03.00.078.6%

Fundamentals of Ilyang

About Ilyang Pharm

Ilyang Pharmaceutical Co.,Ltd operates as a pharmaceutical company primarily in South Korea. The company offers anticancer, circulatory system, endocrine/metabolism, cheonjiyang, female hormone, urinary system, ophthalmology, liver disease, anti-inflammatory analgesic, digestive system, dermatology, respiratory system, nutrient infusion, and neurology medicines. It also provides antibiotics, antifungal drugs, anti-inflammatory analgesic drugs, insecticides, and vaccines; and health drinks, daily food, supplements, health food, cosmetics, and beverages. In addition, the company offers pharmaceutical raw materials products, such as aluminum hydroxide gel, dried aluminum hydroxide gel, magnesium hydroxide, magnesium hydroxide gel, aluminum hydroxide-magnesium carbonate co-dried gel, magnesium trisilicate, hydrotalcite, almagate, aluminum phosphate, aluminum phosphate gel, aluminum magnesium metasilicate, aluminum magnesium silicate, aluminum magnesium silicopolydrate, magaldrate, magaldrate wet gel, dihydroxy aluminum sodium carbonate, magnesium carbonate, aluminum magnesium hydroxide, synthetic aluminum silicate, and other products. Ilyang Pharmaceutical Co.,Ltd also exports its products. The company was formerly known as Il-Yang Pharm. Ind. Co. and changed its name to Ilyang Pharmaceutical Co., Ltd. in May 1991. Ilyang Pharmaceutical Co.,Ltd was founded in 1946 and is headquartered in Yongin, South Korea.

Fundamental data was last updated by Penke on 2024-03-24 08:23:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is fair priced.

1.1. Profitability of Ilyang Pharm.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Ilyang earns for each ₩1 of revenue.

  • Above 10% is considered healthy but always compare Ilyang to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 4.4% means that ₩0.04 for each ₩1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Ilyang Pharm:

  • The MRQ is 4.4%. The company is making a profit. +1
  • The TTM is 4.4%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ4.4%TTM4.4%0.0%
TTM4.4%YOY5.0%-0.6%
TTM4.4%5Y3.9%+0.5%
5Y3.9%10Y1.9%+2.0%
1.1.2. Return on Assets

Shows how efficient Ilyang is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Ilyang to the Drug Manufacturers - Specialty & Generic industry mean.
  • 3.2% Return on Assets means that Ilyang generated ₩0.03 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Ilyang Pharm:

  • The MRQ is 3.2%. Using its assets, the company is less efficient in making profit.
  • The TTM is 3.2%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ3.2%TTM3.2%0.0%
TTM3.2%YOY3.9%-0.6%
TTM3.2%5Y3.0%+0.3%
5Y3.0%10Y1.5%+1.5%
1.1.3. Return on Equity

Shows how efficient Ilyang is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Ilyang to the Drug Manufacturers - Specialty & Generic industry mean.
  • 5.9% Return on Equity means Ilyang generated ₩0.06 for each ₩1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Ilyang Pharm:

  • The MRQ is 5.9%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 5.9%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ5.9%TTM5.9%0.0%
TTM5.9%YOY8.2%-2.3%
TTM5.9%5Y6.2%-0.3%
5Y6.2%10Y3.0%+3.1%

1.2. Operating Efficiency of Ilyang Pharm.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Ilyang is operating .

  • Measures how much profit Ilyang makes for each ₩1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Ilyang to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated ₩0.00  for each ₩1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Ilyang Pharm:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY10.5%-10.5%
TTM-5Y8.3%-8.3%
5Y8.3%10Y8.0%+0.3%
1.2.2. Operating Ratio

Measures how efficient Ilyang is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.52 means that the operating costs are ₩1.52 for each ₩1 in net sales.

Let's take a look of the Operating Ratio trends of Ilyang Pharm:

  • The MRQ is 1.521. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.521. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.521TTM1.5210.000
TTM1.521YOY1.332+0.189
TTM1.5215Y1.383+0.139
5Y1.38310Y1.414-0.031

1.3. Liquidity of Ilyang Pharm.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Ilyang is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 0.82 means the company has ₩0.82 in assets for each ₩1 in short-term debts.

Let's take a look of the Current Ratio trends of Ilyang Pharm:

  • The MRQ is 0.820. The company is just not able to pay all its short-term debts. -1
  • The TTM is 0.820. The company is just not able to pay all its short-term debts. -1
Trends
Current periodCompared to+/- 
MRQ0.820TTM0.8200.000
TTM0.820YOY1.074-0.254
TTM0.8205Y0.958-0.137
5Y0.95810Y0.904+0.053
1.3.2. Quick Ratio

Measures if Ilyang is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Ilyang to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.38 means the company can pay off ₩0.38 for each ₩1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Ilyang Pharm:

  • The MRQ is 0.383. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.383. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.383TTM0.3830.000
TTM0.383YOY0.351+0.032
TTM0.3835Y0.389-0.006
5Y0.38910Y0.425-0.037

1.4. Solvency of Ilyang Pharm.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Ilyang assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Ilyang to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.45 means that Ilyang assets are financed with 44.9% credit (debt) and the remaining percentage (100% - 44.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Ilyang Pharm:

  • The MRQ is 0.449. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.449. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.449TTM0.4490.000
TTM0.449YOY0.414+0.035
TTM0.4495Y0.4490.000
5Y0.44910Y0.486-0.037
1.4.2. Debt to Equity Ratio

Measures if Ilyang is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Ilyang to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 81.6% means that company has ₩0.82 debt for each ₩1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Ilyang Pharm:

  • The MRQ is 0.816. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.816. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.816TTM0.8160.000
TTM0.816YOY0.879-0.063
TTM0.8165Y0.943-0.127
5Y0.94310Y1.071-0.128

2. Market Valuation of Ilyang Pharm

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₩1 in earnings Ilyang generates.

  • Above 15 is considered overpriced but always compare Ilyang to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 24.42 means the investor is paying ₩24.42 for every ₩1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Ilyang Pharm:

  • The EOD is 22.356. Based on the earnings, the company is fair priced.
  • The MRQ is 24.416. Based on the earnings, the company is fair priced.
  • The TTM is 24.416. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD22.356MRQ24.416-2.059
MRQ24.416TTM24.4160.000
TTM24.416YOY18.192+6.223
TTM24.4165Y45.866-21.450
5Y45.86610Y52.784-6.918
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Ilyang Pharm:

  • The EOD is 37.484. Based on how much money comes from the company's main activities, the company is fair priced.
  • The MRQ is 40.936. Based on how much money comes from the company's main activities, the company is fair priced.
  • The TTM is 40.936. Based on how much money comes from the company's main activities, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD37.484MRQ40.936-3.453
MRQ40.936TTM40.9360.000
TTM40.936YOY37.229+3.708
TTM40.9365Y28.112+12.824
5Y28.11210Y38.500-10.388
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Ilyang is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 1.43 means the investor is paying ₩1.43 for each ₩1 in book value.

Let's take a look of the Price to Book Ratio trends of Ilyang Pharm:

  • The EOD is 1.311. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.432. Based on the equity, the company is underpriced. +1
  • The TTM is 1.432. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.311MRQ1.432-0.121
MRQ1.432TTM1.4320.000
TTM1.432YOY1.199+0.233
TTM1.4325Y2.249-0.817
5Y2.24910Y2.688-0.439
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Ilyang Pharm compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---5207.594-5207.5940%1208.737-531%-119.986-98%69.704-7571%
Book Value Per Share--10928.65710928.6570%16136.251-32%13536.158-19%12486.716-12%
Current Ratio--0.8200.8200%1.074-24%0.958-14%0.904-9%
Debt To Asset Ratio--0.4490.4490%0.414+8%0.4490%0.486-8%
Debt To Equity Ratio--0.8160.8160%0.879-7%0.943-13%1.071-24%
Dividend Per Share--155.234155.2340%217.963-29%288.756-46%266.955-42%
Eps--640.981640.9810%1063.642-40%728.158-12%367.763+74%
Free Cash Flow Per Share--382.300382.3000%519.761-26%1348.627-72%1111.580-66%
Free Cash Flow To Equity Per Share--382.300382.3000%-773.751+302%38.118+903%301.380+27%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--15594.813--------
Intrinsic Value_10Y_min---9348.855--------
Intrinsic Value_1Y_max--1397.921--------
Intrinsic Value_1Y_min--601.235--------
Intrinsic Value_3Y_max--4325.776--------
Intrinsic Value_3Y_min--485.023--------
Intrinsic Value_5Y_max--7405.073--------
Intrinsic Value_5Y_min---1078.544--------
Market Cap257535894000.000-9%281258670000.000281258670000.0000%349980721650.000-20%550064468730.000-49%600452296865.000-53%
Net Profit Margin--0.0440.0440%0.050-11%0.039+14%0.019+132%
Operating Margin----0%0.105-100%0.083-100%0.080-100%
Operating Ratio--1.5211.5210%1.332+14%1.383+10%1.414+8%
Pb Ratio1.311-9%1.4321.4320%1.199+19%2.249-36%2.688-47%
Pe Ratio22.356-9%24.41624.4160%18.192+34%45.866-47%52.784-54%
Price Per Share14330.000-9%15650.00015650.0000%19350.000-19%30280.000-48%33170.000-53%
Price To Free Cash Flow Ratio37.484-9%40.93640.9360%37.229+10%28.112+46%38.500+6%
Price To Total Gains Ratio-2.836+8%-3.098-3.0980%13.563-123%18.204-117%126.884-102%
Quick Ratio--0.3830.3830%0.351+9%0.389-2%0.425-10%
Return On Assets--0.0320.0320%0.039-16%0.030+9%0.015+117%
Return On Equity--0.0590.0590%0.082-28%0.062-5%0.030+93%
Total Gains Per Share---5052.360-5052.3600%1426.700-454%168.769-3094%336.659-1601%
Usd Book Value--137485347.895137485347.8950%204297865.919-33%171875364.144-20%158225436.131-13%
Usd Book Value Change Per Share---3.645-3.6450%0.846-531%-0.084-98%0.049-7571%
Usd Book Value Per Share--7.6507.6500%11.295-32%9.475-19%8.741-12%
Usd Dividend Per Share--0.1090.1090%0.153-29%0.202-46%0.187-42%
Usd Eps--0.4490.4490%0.745-40%0.510-12%0.257+74%
Usd Free Cash Flow--4809429.7934809429.7930%6580585.501-27%17165294.476-72%14110341.580-66%
Usd Free Cash Flow Per Share--0.2680.2680%0.364-26%0.944-72%0.778-66%
Usd Free Cash Flow To Equity Per Share--0.2680.2680%-0.542+302%0.027+903%0.211+27%
Usd Market Cap180275125.800-9%196881069.000196881069.0000%244986505.155-20%385045128.111-49%420316607.806-53%
Usd Price Per Share10.031-9%10.95510.9550%13.545-19%21.196-48%23.219-53%
Usd Profit--8063709.8928063709.8920%13466555.900-40%9240808.298-13%4671101.139+73%
Usd Revenue--181329584.275181329584.2750%268667575.246-33%235494385.507-23%207523782.056-13%
Usd Total Gains Per Share---3.537-3.5370%0.999-454%0.118-3094%0.236-1601%
 EOD+5 -3MRQTTM+0 -0YOY+5 -305Y+9 -2610Y+13 -22

3.2. Fundamental Score

Let's check the fundamental score of Ilyang Pharm based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1522.356
Price to Book Ratio (EOD)Between0-11.311
Net Profit Margin (MRQ)Greater than00.044
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.383
Current Ratio (MRQ)Greater than10.820
Debt to Asset Ratio (MRQ)Less than10.449
Debt to Equity Ratio (MRQ)Less than10.816
Return on Equity (MRQ)Greater than0.150.059
Return on Assets (MRQ)Greater than0.050.032
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of Ilyang Pharm based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5048.356
Ma 20Greater thanMa 5014,297.500
Ma 50Greater thanMa 10014,385.800
Ma 100Greater thanMa 20014,706.300
OpenGreater thanClose14,420.000
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in KRW. All numbers in thousands.

Summary
Total Assets356,660,994
Total Liabilities160,253,354
Total Stockholder Equity196,407,640
 As reported
Total Liabilities 160,253,354
Total Stockholder Equity+ 196,407,640
Total Assets = 356,660,994

Assets

Total Assets356,660,994
Total Current Assets114,198,257
Long-term Assets242,462,737
Total Current Assets
Cash And Cash Equivalents 79,705
Short-term Investments 6,775,804
Net Receivables 46,466,119
Inventory 51,784,398
Other Current Assets 751,542
Total Current Assets  (as reported)114,198,257
Total Current Assets  (calculated)105,857,568
+/- 8,340,689
Long-term Assets
Property Plant Equipment 173,626,426
Intangible Assets 27,255,417
Long-term Assets  (as reported)242,462,737
Long-term Assets  (calculated)200,881,844
+/- 41,580,893

Liabilities & Shareholders' Equity

Total Current Liabilities139,191,499
Long-term Liabilities21,061,855
Total Stockholder Equity196,407,640
Total Current Liabilities
Short Long Term Debt 65,788,604
Accounts payable 25,733,986
Other Current Liabilities 1
Total Current Liabilities  (as reported)139,191,499
Total Current Liabilities  (calculated)91,522,590
+/- 47,668,908
Long-term Liabilities
Long term Debt 6,000,000
Capital Lease Obligations Min Short Term Debt545,646
Long-term Liabilities  (as reported)21,061,855
Long-term Liabilities  (calculated)6,545,646
+/- 14,516,209
Total Stockholder Equity
Retained Earnings 25,553,216
Total Stockholder Equity (as reported)196,407,640
Total Stockholder Equity (calculated)25,553,216
+/- 170,854,423
Other
Capital Stock48,826,860
Common Stock Shares Outstanding 17,972
Net Debt 71,708,899
Net Invested Capital 267,083,544
Net Working Capital -24,993,242
Property Plant and Equipment Gross 254,930,977



Balance Sheet

Currency in KRW. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312009-12-312004-12-312003-12-312002-12-31
> Total Assets 
174,238,263
168,294,082
190,534,046
289,864,311
398,383,754
430,830,075
431,625,086
431,263,403
436,373,966
432,253,279
437,456,053
439,116,735
494,271,353
498,185,237
356,660,994
356,660,994498,185,237494,271,353439,116,735437,456,053432,253,279436,373,966431,263,403431,625,086430,830,075398,383,754289,864,311190,534,046168,294,082174,238,263
   > Total Current Assets 
0
0
0
0
129,806,972
158,517,973
146,844,823
147,671,966
166,135,283
161,380,657
171,407,305
162,495,862
203,559,799
200,727,509
114,198,257
114,198,257200,727,509203,559,799162,495,862171,407,305161,380,657166,135,283147,671,966146,844,823158,517,973129,806,9720000
       Cash And Cash Equivalents 
1,297,733
1,129,747
2,469,915
18,644,149
2,705,290
14,502,603
9,470,975
13,314,613
23,552,613
22,207,099
35,895,887
41,341,387
47,731,882
59,597,053
79,705
79,70559,597,05347,731,88241,341,38735,895,88722,207,09923,552,61313,314,6139,470,97514,502,6032,705,29018,644,1492,469,9151,129,7471,297,733
       Short-term Investments 
5,555,519
7,673,945
15,408,753
1,564,602
558,289
594,843
354,854
43,850
3,306,473
5,460,876
43,521
270,869
34,342,673
5,418,929
6,775,804
6,775,8045,418,92934,342,673270,86943,5215,460,8763,306,47343,850354,854594,843558,2891,564,60215,408,7537,673,9455,555,519
       Net Receivables 
52,284,816
50,799,593
60,859,937
63,404,384
93,139,968
87,932,269
83,474,902
82,492,723
83,956,505
75,514,687
69,475,930
58,678,126
63,156,080
60,151,245
46,466,119
46,466,11960,151,24563,156,08058,678,12669,475,93075,514,68783,956,50582,492,72383,474,90287,932,26993,139,96863,404,38460,859,93750,799,59352,284,816
       Other Current Assets 
1,613,274
1,941,795
3,636,000
3,045,206
2,885,006
8,265,058
3,239,738
3,193,673
3,389,375
8,685,328
12,374,329
6,707,495
10,261,277
6,443,282
751,542
751,5426,443,28210,261,2776,707,49512,374,3298,685,3283,389,3753,193,6733,239,7388,265,0582,885,0063,045,2063,636,0001,941,7951,613,274
   > Long-term Assets 
0
0
0
0
0
0
0
283,591,438
270,238,684
270,872,622
266,048,748
276,620,873
290,711,554
297,457,728
242,462,737
242,462,737297,457,728290,711,554276,620,873266,048,748270,872,622270,238,684283,591,4380000000
       Property Plant Equipment 
78,439,105
75,548,379
78,639,630
152,269,717
182,254,105
201,906,476
204,009,080
198,092,474
193,210,902
186,342,275
182,047,368
185,965,602
198,306,924
199,117,718
173,626,426
173,626,426199,117,718198,306,924185,965,602182,047,368186,342,275193,210,902198,092,474204,009,080201,906,476182,254,105152,269,71778,639,63075,548,37978,439,105
       Goodwill 
165,194
123,896
64,066
0
0
0
0
0
0
0
0
0
0
0
0
00000000000064,066123,896165,194
       Long Term Investments 
0
0
0
0
11,472,861
3,443,360
3,720,471
4,558,661
5,112,851
4,471,207
3,360,006
0
0
0
0
00003,360,0064,471,2075,112,8514,558,6613,720,4713,443,36011,472,8610000
       Intangible Assets 
3,951,276
3,481,246
3,046,845
2,842,621
4,485,793
5,215,861
5,411,576
53,129,124
44,176,447
50,722,903
52,004,142
59,401,008
65,163,772
74,898,136
27,255,417
27,255,41774,898,13665,163,77259,401,00852,004,14250,722,90344,176,44753,129,1245,411,5765,215,8614,485,7932,842,6213,046,8453,481,2463,951,276
       Long-term Assets Other 
0
0
0
0
0
0
0
283,591,438
0
0
0
-1
268,085
267,989
0
0267,989268,085-1000283,591,4380000000
> Total Liabilities 
98,564,566
91,160,606
115,331,610
160,671,908
214,503,178
247,367,221
220,624,380
213,908,434
225,390,337
222,373,236
214,716,739
194,194,688
222,513,276
206,331,142
160,253,354
160,253,354206,331,142222,513,276194,194,688214,716,739222,373,236225,390,337213,908,434220,624,380247,367,221214,503,178160,671,908115,331,61091,160,60698,564,566
   > Total Current Liabilities 
62,185,255
62,453,096
80,319,096
97,378,246
146,398,017
168,868,019
178,111,418
182,430,828
206,706,688
183,689,977
180,329,326
177,147,330
198,209,855
186,859,386
139,191,499
139,191,499186,859,386198,209,855177,147,330180,329,326183,689,977206,706,688182,430,828178,111,418168,868,019146,398,01797,378,24680,319,09662,453,09662,185,255
       Short-term Debt 
0
0
0
0
171,470,180
44,329,370
30,846,990
135,163,759
147,390,950
117,771,203
109,662,960
0
0
0
0
0000109,662,960117,771,203147,390,950135,163,75930,846,99044,329,370171,470,1800000
       Short Long Term Debt 
0
0
0
0
171,470,180
44,329,370
30,846,990
135,163,759
147,390,950
117,771,203
109,662,960
102,740,727
96,057,566
84,612,160
65,788,604
65,788,60484,612,16096,057,566102,740,727109,662,960117,771,203147,390,950135,163,75930,846,99044,329,370171,470,1800000
       Accounts payable 
7,940,268
8,178,544
8,837,127
10,401,859
13,419,517
16,331,446
18,979,052
19,477,121
22,341,833
21,941,238
25,271,380
23,663,081
26,856,218
37,629,736
25,733,986
25,733,98637,629,73626,856,21823,663,08125,271,38021,941,23822,341,83319,477,12118,979,05216,331,44613,419,51710,401,8598,837,1278,178,5447,940,268
       Other Current Liabilities 
21,609,560
15,133,080
44,744,325
14,642,907
15,218,952
26,830,913
25,364,449
27,568,489
36,753,782
43,793,582
45,161,246
50,570,160
74,822,644
63,936,392
1
163,936,39274,822,64450,570,16045,161,24643,793,58236,753,78227,568,48925,364,44926,830,91315,218,95214,642,90744,744,32515,133,08021,609,560
   > Long-term Liabilities 
0
0
0
0
0
0
0
31,477,606
18,683,650
38,683,259
34,387,413
17,047,358
24,303,421
19,471,757
21,061,855
21,061,85519,471,75724,303,42117,047,35834,387,41338,683,25918,683,65031,477,6060000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
-171,470,180
-44,329,370
-30,846,990
-135,163,759
-147,390,950
-117,771,203
-109,222,669
300,619
1,002,965
1,103,209
545,646
545,6461,103,2091,002,965300,619-109,222,669-117,771,203-147,390,950-135,163,759-30,846,990-44,329,370-171,470,1800000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
1
0
1
0
0
001010000000000
       Deferred Long Term Liability 
0
0
0
0
31,686,376
35,227,217
45,427,812
37,928,432
38,093,774
46,292,242
48,043,953
55,746,859
61,417,511
70,364,393
0
070,364,39361,417,51155,746,85948,043,95346,292,24238,093,77437,928,43245,427,81235,227,21731,686,3760000
> Total Stockholder Equity
72,674,532
74,381,566
73,012,891
123,881,602
182,767,876
173,423,922
193,796,557
199,607,822
191,948,464
187,485,662
196,897,791
207,193,813
224,114,795
234,653,636
196,407,640
196,407,640234,653,636224,114,795207,193,813196,897,791187,485,662191,948,464199,607,822193,796,557173,423,922182,767,876123,881,60273,012,89174,381,56672,674,532
   Common Stock
35,256,315
35,256,315
35,256,315
35,256,315
44,738,140
44,738,140
47,614,960
47,614,960
47,614,960
47,714,160
47,714,160
47,714,160
47,714,160
47,714,160
0
047,714,16047,714,16047,714,16047,714,16047,714,16047,614,96047,614,96047,614,96044,738,14044,738,14035,256,31535,256,31535,256,31535,256,315
   Retained Earnings Total Equity000000000000000
   Accumulated Other Comprehensive Income 000000000000000
   Capital Surplus 000000000000000
   Treasury Stock000000-7,814,762-7,927,819-8,190,048-7,760,9560-7,332,541-4,171,632-1,662,490-1,659,870
   Other Stockholders Equity 
0
0
0
0
67,480,688
66,110,315
60,380,426
59,354,183
57,620,122
56,057,346
55,836,323
55,901,552
60,587,083
58,495,795
0
058,495,79560,587,08355,901,55255,836,32356,057,34657,620,12259,354,18360,380,42666,110,31567,480,6880000



Balance Sheet

Currency in KRW. All numbers in thousands.




Cash Flow

Currency in KRW. All numbers in thousands.




Income Statement

Currency in KRW. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue259,042,263
Cost of Revenue-149,374,068
Gross Profit109,668,195109,668,195
 
Operating Income (+$)
Gross Profit109,668,195
Operating Expense-244,691,842
Operating Income14,350,421-135,023,648
 
Operating Expense (+$)
Research Development23,747,861
Selling General Administrative23,516,046
Selling And Marketing Expenses0
Operating Expense244,691,84247,263,907
 
Net Interest Income (+$)
Interest Income184,535
Interest Expense-3,215,846
Other Finance Cost-1
Net Interest Income-3,031,312
 
Pretax Income (+$)
Operating Income14,350,421
Net Interest Income-3,031,312
Other Non-Operating Income Expenses0
Income Before Tax (EBT)12,951,91014,350,421
EBIT - interestExpense = -3,215,846
11,519,586
14,735,432
Interest Expense3,215,846
Earnings Before Interest and Taxes (EBIT)016,167,756
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax12,951,910
Tax Provision-1,432,324
Net Income From Continuing Ops11,519,58611,519,586
Net Income11,519,586
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net03,031,312
 

Technical Analysis of Ilyang
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Ilyang. The general trend of Ilyang is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Ilyang's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Ilyang Pharm.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 15,020 < 16,080 < 16,250.

The bearish price targets are: 13,910 > 13,900 > 13,130.

Tweet this
Ilyang Pharm Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Ilyang Pharm. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Ilyang Pharm Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Ilyang Pharm. The current macd is 29.94.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Ilyang price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Ilyang. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Ilyang price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Ilyang Pharm Daily Moving Average Convergence/Divergence (MACD) ChartIlyang Pharm Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Ilyang Pharm. The current adx is 16.70.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Ilyang shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Ilyang Pharm Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Ilyang Pharm. The current sar is 14,172.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Ilyang Pharm Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Ilyang Pharm. The current rsi is 48.36. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Ilyang Pharm Daily Relative Strength Index (RSI) ChartIlyang Pharm Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Ilyang Pharm. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Ilyang price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Ilyang Pharm Daily Stochastic Oscillator ChartIlyang Pharm Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Ilyang Pharm. The current cci is 8.62448297.

Ilyang Pharm Daily Commodity Channel Index (CCI) ChartIlyang Pharm Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Ilyang Pharm. The current cmo is -5.29202582.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Ilyang Pharm Daily Chande Momentum Oscillator (CMO) ChartIlyang Pharm Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Ilyang Pharm. The current willr is -59.81308411.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Ilyang is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Ilyang Pharm Daily Williams %R ChartIlyang Pharm Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Ilyang Pharm.

Ilyang Pharm Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Ilyang Pharm. The current atr is 268.29.

Ilyang Pharm Daily Average True Range (ATR) ChartIlyang Pharm Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Ilyang Pharm. The current obv is 5,896,989.

Ilyang Pharm Daily On-Balance Volume (OBV) ChartIlyang Pharm Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Ilyang Pharm. The current mfi is 47.33.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Ilyang Pharm Daily Money Flow Index (MFI) ChartIlyang Pharm Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Ilyang Pharm.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-08STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-09STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-14STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-11-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-11-17STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-20STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-11-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-07MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-15STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-02BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-15BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-24WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-31DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-01STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-20CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-28CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-25ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside

6.3. Candlestick Patterns

Ilyang Pharm Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Ilyang Pharm based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5048.356
Ma 20Greater thanMa 5014,297.500
Ma 50Greater thanMa 10014,385.800
Ma 100Greater thanMa 20014,706.300
OpenGreater thanClose14,420.000
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Ilyang with someone you think should read this too:
  • Are you bullish or bearish on Ilyang? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Ilyang? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Ilyang Pharm

I send you an email if I find something interesting about Ilyang Pharm.


Comments

How you think about this?

Leave a comment

Stay informed about Ilyang Pharm.

Receive notifications about Ilyang Pharm in your mailbox!